Entry into a Material Definitive Agreement

SEC Filing Summary: Ekso Bionics Holdings, Inc. (8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Ekso Bionics Holdings, Inc. on June 8, 2023, covering events occurring on June 8, 2023, and June 12, 2023. The registrant is an emerging growth company incorporated in Nevada, with its principal executive offices in San Rafael, California. The filing details the results of the 2023 Annual Meeting of Stockholders and an amendment to an existing securities offering agreement.

Key Financial Metrics and Capital Activities

The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for a reporting period. However, it discloses specific capital activity under the At-the-Market (ATM) Offering Agreement:

  • Shares Sold: 77,594 shares of common stock issued and sold to date under the agreement.
  • Average Price: $10.72 per share.
  • Net Proceeds: Approximately $791,217 (net of commission and expenses).
  • Remaining Capacity: $6,668,332 remains available for future offerings under the prospectus supplement.

Material Changes and Corporate Actions

Amendment to Offering Agreement: On June 12, 2023, the Company amended its Sales Agreement with H.C. Wainwright & Co., LLC. The primary change was the removal of the $6.75 per share floor sales price, allowing for greater flexibility in share sales. The agreement otherwise remains unchanged.

Annual Meeting Results: On June 8, 2023, stockholders voted on four proposals, all of which were approved:

  1. Election of Directors: Five nominees (Scott G. Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, and Rhonda A. Wallen) were elected to the Board of Directors.
  2. Equity Plan Amendment: The 2014 Equity Incentive Plan was amended to increase the authorized share pool from 2,524,286 to 3,724,286 shares.
  3. Executive Compensation: An advisory vote approved the compensation of named executive officers.
  4. Auditor Ratification: The appointment of WithumSmith+Brown, PC as the independent auditor for the fiscal year ending December 31, 2023, was ratified.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding the offer of securities. The removal of the price floor in the ATM agreement may expose the company to selling shares at lower prices in the future, though no specific risk analysis is provided in this text.

Key Facts for Investor Verification

  • Verify the impact of removing the $6.75 price floor on future share issuance pricing and potential dilution.
  • Confirm the total number of shares authorized under the amended Equity Incentive Plan (3,724,286) and the remaining unissued balance.
  • Review the full text of Amendment No. 1 to the At-the-Market Offering Agreement (Exhibit 10.1) for any other modified terms.
  • Check the Company's proxy statement filed on April 28, 2023, for detailed background on the director nominees and executive compensation.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.